BridgeBio Oncology Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
BBOT$2.30+12.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities · (unaudited) | ||
| Net loss | $(42,106) | $(22,055) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation of property and equipment | 74 | 54 |
| Stock-based compensation | 3,871 | 627 |
| Change in fair value of participation right liability | — | 725 |
| Net accretion of premiums on marketable securities | (74) | (408) |
| Amortization of right-of-use assets | 112 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (7,531) | 251 |
| Other non-current assets | 1,329 | (31) |
| Accounts payable | 10,685 | 537 |
| Accrued compensation and benefits | (3,729) | (1,920) |
| Accrued research and development liabilities | (31) | 2,341 |
| Accrued professional services | 880 | 219 |
| Operating lease liabilities | (123) | — |
| Other accrued liabilities | 305 | 13 |
| Balances due to and from related parties | 421 | 48 |
| Net cash used in operating activities | (35,917) | (19,599) |
| Investing activities | ||
| Maturities of marketable securities | 26,262 | 39,963 |
| Purchases of marketable securities | (311,645) | (24,433) |
| Purchases of property and equipment | (24) | (162) |
| Net cash (used in) provided by investing activities | (285,407) | 15,368 |
| Financing activities | ||
| Payment of deferred transaction costs | (121) | (404) |
| Exercise of common stock options for cash | 416 | — |
| Net cash provided by (used in) financing activities | 295 | (404) |
| Net decrease in cash, cash equivalents, and restricted cash | (321,029) | (4,635) |
| Cash, cash equivalents, and restricted cash at beginning of period | 373,819 | 30,983 |
| Cash, cash equivalents, and restricted cash at end of period | $52,790 | $26,348 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Right-of-use asset recognized in exchange for operating lease liabilities | $— | $2,706 |
| Deferred de-SPAC transaction costs included in accrued professional services and other accrued liabilities | $— | $2,493 |
| Unpaid property and equipment included in accounts payable and other accrued liabilities | $32 | $55 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.